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The complex formed by interaction between an antibody molecule and its corresponding antigen can be detected on a silicon substrate by an optical sensor, as described in previous reports (1, 2 ) . For processing and modification of the silicon substrate surface, silicon wafers were cut into ϳ2 ϫ 0.7 cm rectangles and made hydrophilic by immersion in an acidic peroxide solution (300 g/L H 2 O 2 -980 g/L H 2 SO 4 ; 1:3 by volume) and light shaking in a shaker for 30 min. The solution not only removed contaminants from the silicon surface but also increased the number of silanol groups on the surface. The hydrophilic surfaces were rinsing in distilled water 3 times and in absolute ethanol 3 times, then incubated in a mixture of 3-aminopropyltriethoxysilane and ethanol (1:15 by volume) and shaken lightly in a shaker for 2 h; The mixture liquid was then removed, and the silicon wafers were rinsed in absolute ethanol 3 times and in phosphate-buffered saline (PBS) buffer 3 times, then placed in a mixture of glutaraldehyde and PBS (1:10 by volume), shaken lightly in a shaker for 1 h, and finally, washed in PBS buffer 3 times and left in a beaker with PBS buffer until use. Through the reaction of glutaraldehyde with 3-aminopropyltriethoxysilane, Fc regions of the antibody molecules were covalently immobilized on the chip surfaces. The OPC detection procedure was performed at least twice for each sample. Quantitative analysis was performed with use of a calibration curve, which was constructed with a serum sample with a known concentration of CA15-3 that had been determined by an electrochemiluminescence immunoassay (ECLIA). CA15-3 was undetectable in 30 serum samples from healthy blood donors. ROC plot analysis (4 ) was used to assess the accuracy of (Left), image in grayscale of anti-CA15-3 antibody immobilized after reaction with patient serum containing CA15-3 antigen. (Right), image in three dimensions deduced from (the data on the left) according to the principle that the intensity in the image is proportional to the square of the thin layer thickness. 1a and 4c, spots containing anti-CA15-3 IgG as a control; the mean thickness of the anti-CA15-3 IgG layer is 6.4 nm. 2a-3c, spots containing CA15-3/anti-CA15-3 complex formed by different samples from patients with breast cancer.
the OPC test and to compare it with ECLIA detection in 60 serum samples from patients.
The CA15-3 image format determined by the OPC test is shown in Fig. 1 . The calibration curve was approximated by the equation: y ϭ 1 Ϫ e Ϫ , which was usable up to ϳ 20 kIU/L. Test samples need to be diluted when if their concentrations are Ն20 kIU/L (Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol51/ issue6/). The within-run imprecision (CV) values were 5.2%, 2.5%, and 4.6% at 5, 10, and 18 kIU/L, respectively (n ϭ 10), and the interassay CVs were 7.5%, 3.8%, and 6.3%. The lower limit of detection was 1 kIU/L at a signal-to-noise ratio of 3. The limit of quantification, defined as the lowest amount detectable with imprecision (CV) Ͻ20% (n ϭ 10), was 4 kIU/L.
Because CA15-3 is most useful for monitoring advanced breast cancer (5, 6 ), we collected 60 serum samples from women with breast cancer and other breast diseases for a preliminary clinical study of our test. The median patient age was 48.5 years (range, 22-75 years). Study patients included 24 women with intraductal carcinoma, 15 women with mucinous carcinoma, 5 women with in situ lobular carcinoma, 2 women with medullary carcinoma, and 14 women with breast diseases but no evidence of cancer. We also collected 30 serum samples from healthy blood donors. Serum was separated from the blood cells and stored at Ϫ70°C until analysis. OPC tests were performed with an optical biosensor system; this immunosensor system is based on imaging ellipsometry developed at the Institute of Mechanics, China Academy of Sciences. For comparison, we measured CA 15-3 by an ECLIA on an Elecsys 2010 system (Roche Diagnostics). Both tests were done without knowledge of the clinical status of the patients or knowledge of the results of the other test. The results obtained by ECLIA detection (kIU/L) and the OPC method (kIU/L) were compared by use of Bland-Altman plots with Analyze-it Software (GeneralϩClinical Laboratory statistics, Ver. 1.71; Fig. 2 in the online Data Supplement). The areas under the ROC curves for differentiating women with breast cancer from healthy women and women with other breast diseases were 0.807 (95% confidence interval, 0.695-0.919) for the OPC test and 0.882 (95% confidence interval, 0.776 -0.998) for the ECLIA test (Fig. 3 in the online Data Supplement).
Compared with the Biacore system, a fairly widely applied optical detection method based on surface plasmon resonance, the OPC technology used in this study also allows label-free samples and crude samples to be used directly without previous purification. Both technologies are based on the optical sensor principle, but OPC is a direct optical visualization method based on imaging ellipsometry that offers biomolecular layer visualization with a distinct graph and qualitative and quantitative result analysis. Compared with the Biacore method, the OPC technology has advantages such as (a) optical sampling without disturbance; (b) identification, detection, and purification of biomolecules not only by antigenantibody interactions but also by receptor-ligand interactions; and (c) real-time detection and monitoring of biomolecular interactions between carbohydrates, proteins, and nuclear acids. The OPC setup used in this study has some unique advantages. The multibioprobe analysis for 1 analyte allows up to 24 bioprobes to be arrayed on a chip at the same time, or multianalyte analysis for 1 bioprobe can be arrayed on a chip allowing up to 24 different samples at the same time. Compared with the Biacore system, a disadvantage of the OPC system is that it is not easy to use because of the complicated physical requirements of the current system.
The power and flexibility of proteomic analysis techniques, which facilitate protein separation, identification, and characterization, should hasten our understanding of processes at the protein level (7 ) . The combination of imaging ellipsometry and protein chip technology provides a new potential biosensor system for detection and monitoring of biomolecular interaction events for the fields of proteomics, clinical laboratory testing, and biomolecular interaction research.
